Treatment Patterns in Castrate Resistant Prostate Cancer Patients with Bone Metastases in a Medicare Population
The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.
- First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period - Members age ≥ 55 to 89 years at index - Medicare members with medical and pharmacy coverage; and - Continuously enrolled during the pre- and post-index periods.
- Member with diagnosis of any other cancer (excluding melanoma (ICD-9 172.x) and other metastases (ICD-9 198.x)) before the index date; and - Members age ≥ 89 years of age at index date
Louisville, United States
E-mail: [email protected]
Phone: Not Available
Treatment Patterns in Castrate Resistant Prostate Cancer Patients with Bone Metastases